S2B Syn2bio S.A.
67.80PLN+1.80%Mkt Cap: 147.24M $P/E: —1d ago
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery…
Industry Peers
Biotechnology$127.54BUSDP/E 29.3
$81.13BUSD
$74.79BUSDP/E 18.0
$57.11BUSDP/E 34.8
$55.24BUSDP/E 36.1
$44.51BUSD
$41.63BUSDP/E 17.7
$41.14BUSDP/E 64.7
$32.74BUSDP/E 30.1
$29.42BUSDP/E 37.1
$25.84BUSD
$24.53BUSD
$24.01BUSDP/E 30.3
$23.13BUSDP/E 14.5
$22.67BUSD
$21.61BUSDP/E 29.3
$15.32BUSDP/E 16.2
$15.01BUSDP/E 17.5
$14.58BUSDP/E 18.6
$13.78BUSD
Key Statistics
Company
Market Cap147.24M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-5.99M USD
Revenue/Share—
Last Price67.80 PLN
Fiscal Year End—
MR Quarter—
Employees—
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLSNBIO00013
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-2.71
EPS (Forward)—
52W Range
26.2059% of range96.60
52W High96.60 PLN
52W Low26.20 PLN
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-141.89%
ROA-90.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.12M USD
CapEx (TTM)222.41K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 PLN
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)31.00 PLN
Upside (mean)-54.3%
Target Range31.00 PLN – 31.00 PLN
# Analysts1
Ownership
Shares Out.8.73M
Float—
Insiders39.79%
Institutions8.48%
Technical
SMA 5065.74 (+3.1%)
SMA 20052.76 (+28.5%)
Beta—
S&P 52W Chg14.58%
Avg Vol (30d)37.72K
Avg Vol (10d)27.02K
Technical Indicators
RSI (14)49.8
MACD0.9867
MACD Signal1.3308
MACD Hist.-0.3441
BB Upper74.55 PLN
BB Middle67.48 PLN
BB Lower60.40 PLN
BB Width20.98%
ATR (14)4.126 PLN
Vol Ratio (20d)0.50x